Redx Pharma Plc (LON:REDX – Get Rating)’s share price crossed below its 50 day moving average during trading on Wednesday . The stock has a 50 day moving average of GBX 64.79 ($0.79) and traded as low as GBX 60 ($0.74). Redx Pharma shares last traded at GBX 61.50 ($0.75), with a volume of 65,730 shares trading hands.
Redx Pharma Trading Down 7.5 %
The firm has a market cap of £205.01 million and a P/E ratio of -7.32. The business’s 50-day moving average is GBX 64.79 and its two-hundred day moving average is GBX 70.12. The company has a debt-to-equity ratio of 331.56, a current ratio of 2.11 and a quick ratio of 1.93.
About Redx Pharma
Redx Pharma Plc engages in drug discovery, pre-clinical development, and licensing activities in the United Kingdom. It discovers and develops small molecule drugs for treating anti-cancer and fibrosis targets in the areas of unmet medical needs. The company also develops RXC004, a porcupine inhibitor that is in Phase II clinical trial for targeted therapy of Wnt-ligand driven cancer; and RXC007, an oral selective rho associated coiled-coil containing protein kinase 2 (ROCK2) inhibitor for the treatment of fibrotic diseases.
- Two High-Yield Deep-Values You Shouldn’t Ignore
- Is Starbucks Shooting For The Moon?
- PayPal Continues To Struggle As Competition Increases
- Is Nike An Undervalued Opportunity for Investors?
- Proposed Tesla Stock Split Drives EV Market Higher
Want More Great Investing Ideas?
- Bear Market Game Plan!
- The 10 Best Stocks to Own in 2022
- 7 Stocks to Buy and Hold Forever
- 3 Stocks to DOUBLE This Year
Receive News & Ratings for Redx Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Redx Pharma and related companies with MarketBeat.com's FREE daily email newsletter.